A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD‐8)

@inproceedings{Dungan2016A2S,
  title={A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD‐8)},
  author={Kathleen M Dungan and Raimund Weitgasser and Federico P{\'e}rez Manghi and Ella Pintilei and Jessie L. Fahrbach and Honghua H. Jiang and Jasmine E Shell and Kenneth E Robertson},
  booktitle={Diabetes, obesity & metabolism},
  year={2016}
}
AIMS To evaluate the safety and efficacy of once-weekly dulaglutide 1.5 mg, a long-acting glucagon-like peptide-1 receptor agonist, compared with placebo in patients with type 2 diabetes (T2D) on glimepiride monotherapy. METHODS This phase III, randomized (4 : 1; dulaglutide:placebo), double-blind, placebo-controlled, 24-week study compared the safety and efficacy of once-weekly dulaglutide 1.5 mg with placebo in sulphonylurea-treated (≥half-maximal dose, stable ≥3 months) patients (N = 300… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-4 of 4 extracted citations

Dulaglutide for the treatment of type 2 diabetes.

Expert opinion on biological therapy • 2017